Bandaram Pharma

Who are in the management team of Bandaram Pharma?

As of March 2018, the management team of Bandaram Pharma includes Chairman Kishan Prasad Palayu, Non Executive Directors Mahesh Kumar Vellaboyina and Sangam Venkateshwar Rao, Non Executive Independent Director Namrata Chadha, and Executive Director Shivarama Babu Velchuri, who receives a remuneration of 36.0 lacs.

As of March 2018, the management team of Bandaram Pharma includes:<BR><BR>- Kishan Prasad Palayu, who serves as the Chairman.<BR>- Mahesh Kumar Vellaboyina, who is a Non Executive Director.<BR>- Sangam Venkateshwar Rao, also a Non Executive Director.<BR>- Namrata Chadha, who holds the position of Non Executive Independent Director.<BR>- Shivarama Babu Velchuri, who is the Executive Director.<BR><BR>Shivarama Babu Velchuri is noted to receive a remuneration of 36.0 lacs.

Has Bandaram Pharma declared dividend?

Bandaram Pharma Packtech Ltd has declared a 1% dividend, amounting to 0.1 per share, with an ex-date of September 20, 2024. Total returns have varied significantly across periods, with a 5-year total return of 166.14%, despite some shorter periods showing negative returns.

Bandaram Pharma Packtech Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -15.87%, with a dividend return of 0%, resulting in a total return of -15.87%.<BR><BR>Over the 1-year period, the price return was 7.69%, the dividend return was 0.30%, leading to a total return of 7.99%.<BR><BR>For the 2-year period, the price return was -49.75%, with no dividend return, resulting in a total return of -49.75%.<BR><BR>In the 3-year period, the price return was 0%, and there was no dividend return, leading to a total return of 0.0%.<BR><BR>During the 4-year period, the price return was 165.45%, with no dividend return, resulting in a total return of 165.45%.<BR><BR>For the 5-year period, the price return was 165.45%, with a dividend return of 0.69%, leading to a total return of 166.14%.<BR><BR>Overall, while Bandaram Pharma has declared a dividend, the total returns over various periods show significant variability, with some periods reflecting substantial gains, particularly over the longer term, despite certain periods showing negative returns.

Who are the peers of the Bandaram Pharma?

Bandaram Pharma's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and others, with varying management risks and growth rates. Poly Medicure leads in 1-year returns at 24.29%, while Bandaram Pharma has a return of 14.84%.

Peers: Bandaram Pharma's peers are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Tejnaksh Health., GKB Ophthalmics, KMS Medisurgi, and Medinova Diagno.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Excellent for Bandaram Pharma, Average for Poly Medicure, Indegene, and the rest, while Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Tejnaksh Health., GKB Ophthalmics, KMS Medisurgi, and the rest. Capital Structure is Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest have Below Average or Good capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while the lowest is Amkay Products at -34.33%. Bandaram Pharma's 1-year return is 14.84%, which is significantly higher than Amkay Products but lower than Poly Medicure. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Tejnaksh Health., GKB Ophthalmics, and Amkay Products.

What is the technical trend for Bandaram Pharma?

As of May 5, 2025, Bandaram Pharma's technical trend has shifted to a bearish stance with moderate strength, indicated by bearish signals from the MACD, Bollinger Bands, and moving averages, alongside a bearish monthly RSI.

As of 5 May 2025, the technical trend for Bandaram Pharma has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both signaling bearish trends, alongside a bearish reading from the daily moving averages. The monthly RSI also indicates bearish momentum, while the KST and Dow Theory show mildly bearish conditions on a monthly basis. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Bandaram Pharma.

What does Bandaram Pharma do?

Bandaram Pharma Packtech Ltd is a micro-cap company in the healthcare services industry, focusing on the processing and supply of recycled paper. It was incorporated in 1991 and transitioned to this focus in 2022, reporting net sales of 85 Cr and a net profit of 2 Cr as of March 2025.

Overview:<BR>Bandaram Pharma Packtech Ltd operates in the healthcare services industry, focusing on the processing and supply of recycled paper, and is categorized as a micro-cap company.<BR><BR>History:<BR>Incorporated on December 2, 1991, Bandaram Pharma Packtech Ltd was originally established to manufacture latex gloves. The company later diversified into the paper industry in 2022. As of the latest quarterly results reported for March 2025, the company has transitioned to solely focusing on recycled paper.<BR><BR>Financial Snapshot:<BR>Net Sales: 85 Cr (Quarterly Results - Mar 2025)<BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025)<BR>Market Cap: INR 48 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 48.00<BR>Industry P/E: 53<BR>Dividend Yield: 0.05%<BR>Debt-Equity: 1.35<BR>Return on Equity: 7.83%<BR>Price to Book: 3.77<BR><BR>Contact Details:<BR>Address: 601 5th Floor Oxford Towers, Old Airport Road Kodihalli Bangalore Karnataka : 560008<BR>Email: contact@shivamedicare.com<BR>Website: http://www.bandaram.com

Who are the top shareholders of the Bandaram Pharma?

The top shareholder of Bandaram Pharma is B. Deepak Reddy, holding 39.38% of the shares, with no pledged promoter holdings. The highest public shareholder is Sanivarapu Jhansi at 6.54%, while individual investors collectively own 23.74%.

The top shareholders of Bandaram Pharma include the promoters, with B. Deepak Reddy holding the largest stake at 39.38%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sanivarapu Jhansi, who owns 6.54% of the shares. Additionally, individual investors collectively hold 23.74% of the company's shares.

How big is Bandaram Pharma?

As of 24th July, Bandaram Pharma Packtech Ltd has a market capitalization of 46.00 Cr, with recent net sales of 36.97 Cr and a net profit of 0.99 Cr. The latest balance sheet shows shareholder's funds of 12.28 Cr and total assets of 32.06 Cr.

As of 24th July, Bandaram Pharma Packtech Ltd has a market capitalization of 46.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 36.97 Cr and a Net Profit of 0.99 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 12.28 Cr and Total Assets of 32.06 Cr.

Is Bandaram Pharma overvalued or undervalued?

As of November 28, 2025, Bandaram Pharma is considered overvalued with a PE ratio of 216.00 and a valuation grade of attractive, despite strong short-term returns, due to negative year-to-date and one-year performance.

As of 28 November 2025, Bandaram Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in perception regarding its worth. The company is currently considered overvalued, with a PE ratio of 216.00, a Price to Book Value of 3.71, and an EV to EBITDA of 30.28. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Bandaram Pharma's PE ratio is significantly higher than Lenskart Solutions at 241.34 and Poly Medicure at 54.51, both of which are also considered expensive. The PEG ratio of 51.30 further emphasizes the overvaluation, especially when compared to the industry standards. While Bandaram Pharma has shown strong short-term returns, outperforming the Sensex in the past week and month, its year-to-date and one-year returns are negative, which adds to the concern regarding its current valuation.

How has been the historical performance of Bandaram Pharma?

Bandaram Pharma has shown steady growth in net sales and profit over the past three years, with net sales increasing from 18.73 Cr in Mar'23 to 36.96 Cr in Mar'25, and profit after tax rising from 0.26 Cr to 0.99 Cr. Total assets and liabilities also grew significantly during this period, while cash flow from operating activities remained negative but stable.

Answer:<BR>The historical performance of Bandaram Pharma shows a steady growth in net sales and profit over the past three years.<BR><BR>Breakdown:<BR>Bandaram Pharma's net sales increased from 18.73 Cr in Mar'23 to 34.08 Cr in Mar'24, and further to 36.96 Cr in Mar'25, indicating a consistent upward trend. Total operating income mirrored this growth, reaching 36.96 Cr in Mar'25. The total expenditure also rose, from 17.57 Cr in Mar'23 to 34.14 Cr in Mar'25, primarily driven by raw material costs and employee expenses. Operating profit (PBDIT) improved from 1.35 Cr in Mar'23 to 2.91 Cr in Mar'25, while profit before tax rose from 0.33 Cr to 1.32 Cr in the same period. Profit after tax followed suit, increasing from 0.26 Cr in Mar'23 to 0.99 Cr in Mar'25. The company's total assets grew significantly from 20.17 Cr in Mar'23 to 38.92 Cr in Mar'25, alongside total liabilities which increased from 20.17 Cr to 38.92 Cr. Cash flow from operating activities remained negative but stable at -4.00 Cr in both Mar'24 and Mar'25, while cash flow from financing activities showed a positive trend, reaching 5.00 Cr in Mar'25. Overall, Bandaram Pharma has demonstrated solid growth in sales and profitability, alongside an increase in both assets and liabilities.

When is the next results date for Bandaram Pharma Packtech Ltd?

The next results date for Bandaram Pharma Packtech Ltd is 13 February 2026.

The next results date for Bandaram Pharma Packtech Ltd is scheduled for 13 February 2026.

Are Bandaram Pharma Packtech Ltd latest results good or bad?

Bandaram Pharma Packtech Ltd's latest results show mixed performance; while revenue grew significantly by 92.97% year-on-year, net profit declined by 91.04% compared to last year, and operating margins fell to 3.35%, indicating serious operational challenges. Investors should be cautious due to these profitability issues and high financial leverage.

Bandaram Pharma Packtech Ltd's latest results present a mixed picture, leaning towards the negative due to significant operational challenges despite some positive revenue growth. In Q2 FY26, the company reported a net profit of ₹0.06 crores, which is a 200% increase from the previous quarter. However, this figure represents a staggering 91.04% decline compared to the same quarter last year. <BR><BR>On the revenue front, the company achieved ₹13.72 crores, marking a robust 92.97% year-on-year growth and a 69.38% increase from the previous quarter. This is commendable; however, the operating margin has collapsed to just 3.35%, the lowest in recent quarters, indicating severe issues in cost management and operational efficiency. <BR><BR>The return on equity (ROE) stands at a weak 5.70%, suggesting poor capital efficiency. Additionally, the company's high financial leverage, with a debt-to-equity ratio of approximately 1.35, raises concerns about its financial stability. <BR><BR>Overall, while Bandaram Pharma has shown impressive revenue growth, the drastic decline in profitability and operational margins signals significant underlying issues that could pose risks to its future performance. Investors should approach with caution, as the company appears to be struggling to convert revenue growth into sustainable profits.

Should I buy, sell or hold Bandaram Pharma Packtech Ltd?

Why is Bandaram Pharma Packtech Ltd falling/rising?

As of 05-May, Bandaram Pharma Packtech Ltd's stock price is at 24.85, reflecting a slight increase today but a significant decline over various periods, including a 36.59% drop over the past year. Despite today's price rise, the stock has consistently underperformed against the Sensex and its sector.

As of 05-May, Bandaram Pharma Packtech Ltd's stock price is currently at 24.85, reflecting a change of 0.27, or an increase of 1.1%. Despite this rise in the current price, the stock has shown a significant decline over various periods. Over the past week, it has underperformed with a decrease of 8.51%, while the Sensex has only increased by 0.17%. In the past month, the stock has fallen by 0.88%, compared to a 5.04% gain in the Sensex. Year-to-date, the stock is down 16.53%, while the benchmark has decreased by 9.63%. Over the last year, the stock has plummeted by 36.59%, significantly underperforming the Sensex, which has only declined by 4.68%. Furthermore, the stock has experienced a dramatic drop of 65.94% over the past three years, contrasting sharply with the Sensex's gain of 26.15%. <BR><BR>In terms of today's performance, Bandaram Pharma has underperformed its sector, which has gained by 4.49%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. However, there has been a notable increase in investor participation, with delivery volume rising by 66.12% compared to the 5-day average, suggesting some interest in the stock despite its overall downward trajectory. <BR><BR>In summary, while there is a slight increase in the stock price today, the broader context shows a consistent pattern of decline over various time frames, indicating that Bandaram Pharma Packtech Ltd is facing significant challenges.

Which are the latest news on Bandaram Pharma?